Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04198116 · ClinicalTrials.gov registry record · Phase 2

Combining Varenicline and Guanfacine for Smoking Cessation

A Phase 2 study, sponsored by Yale University.

Completed
Registry status
Phase 2
Development phase
167
Enrollment target

NCT04198116: Completed Phase 2 study, sponsored by Yale University.

NCT04198116 is a Phase 2 study that has completed, run by Yale University. The registered enrollment target is 167 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (26% higher). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04198116, a Phase 2 study, has completed, sponsored by Yale University.

COMPLETED
Registry status
Phase 2
Development phase
167 participants
Enrollment target

Study Summary

The novel design of this study combines a laboratory paradigm to evaluate stress-induced smoking behavior and smoking-related reinforcement, followed by a 12-week treatment phase to evaluate clinical outcomes.

Primary Outcome

Latency (in minutes) to time of first cigarette smoked during the 50-minute delay period.

Interventions

  • DRUG Varenicline
  • DRUG Guanfacine ER

Trial Details

FieldValue
Enrollment Target 167 participants
Start Date 2020-11-01
Est. Completion 2025-04-30
Phase Phase 2
Yale University

1,492 total trials

What the finished NCT04198116 record still lists

NCT04198116 is an interventional study that assigns participants to a tested intervention. The registered 167 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (26% higher).

The record links to 0 conditions, and to 2 interventions - of which Varenicline is the first listed.

NCT04198116 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT04198116 about?

NCT04198116 is a clinical study titled "Combining Varenicline and Guanfacine for Smoking Cessation". The novel design of this study combines a laboratory paradigm to evaluate stress-induced smoking behavior and smoking-related reinforcement, followed by a 12-week treatment phase to evaluate clinical outcomes.

What is the current status of trial NCT04198116?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 167 participants. The study started on 2020-11-01. Estimated completion is 2025-04-30.

What interventions are being tested in trial NCT04198116?

The interventions under investigation include: Varenicline (DRUG), Guanfacine ER (DRUG).

Who is sponsoring clinical trial NCT04198116?

This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT04198116's enrollment target sits among peer trials

167 406th of 2000 higher than 1,595 of 2,000 other Phase 2 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT04248283 · 167 participants · NA

    Adjustable Continence Therapy (ACT) for the Treatment of Female SUI

  • NCT04552509 · 167 participants · NA

    TRUEBEAM Stereotactic Body Radiotherapy for Localized Prostate Cancer

  • NCT05516277 · 167 participants · NA

    Insomnia Treatment and Cardiometabolic Health in Older Adults With Posttraumatic Stress Disorder

  • NCT02118922 · 168 participants

    A Study to Test the Diagnostic Potential of Brillouin Microscopy for Corneal Ectasia

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT04198116, the US trial registry maintained by the National Library of Medicine. NCT04198116 (mid enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.